Appropriate use of beta blockers in cirrhosis

Ranjan Mascarenhas, Atif Zaman

Research output: Contribution to journalArticle

Abstract

Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalCurrent Hepatitis Reports
Volume14
Issue number3
DOIs
StatePublished - Jul 15 2015

Fingerprint

Fibrosis
Developing Countries
Varicose Veins
Developed Countries
Ascites
Liver Cirrhosis
Hemorrhage
Morbidity
Mortality

Keywords

  • Beta blocker
  • Cirrhosis
  • Portal hypertension
  • Refractory ascites
  • Varices

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Appropriate use of beta blockers in cirrhosis. / Mascarenhas, Ranjan; Zaman, Atif.

In: Current Hepatitis Reports, Vol. 14, No. 3, 15.07.2015, p. 243-249.

Research output: Contribution to journalArticle

Mascarenhas, Ranjan ; Zaman, Atif. / Appropriate use of beta blockers in cirrhosis. In: Current Hepatitis Reports. 2015 ; Vol. 14, No. 3. pp. 243-249.
@article{aebba8df176d49edac132917c3726b87,
title = "Appropriate use of beta blockers in cirrhosis",
abstract = "Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.",
keywords = "Beta blocker, Cirrhosis, Portal hypertension, Refractory ascites, Varices",
author = "Ranjan Mascarenhas and Atif Zaman",
year = "2015",
month = "7",
day = "15",
doi = "10.1007/s11901-015-0278-2",
language = "English (US)",
volume = "14",
pages = "243--249",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Appropriate use of beta blockers in cirrhosis

AU - Mascarenhas, Ranjan

AU - Zaman, Atif

PY - 2015/7/15

Y1 - 2015/7/15

N2 - Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.

AB - Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.

KW - Beta blocker

KW - Cirrhosis

KW - Portal hypertension

KW - Refractory ascites

KW - Varices

UR - http://www.scopus.com/inward/record.url?scp=84942305090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942305090&partnerID=8YFLogxK

U2 - 10.1007/s11901-015-0278-2

DO - 10.1007/s11901-015-0278-2

M3 - Article

AN - SCOPUS:84942305090

VL - 14

SP - 243

EP - 249

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 3

ER -